FolioLanternBeta
KROSKeros Therapeutics, Inc.

Keith Regnante

Chief Financial Officer at Keros Therapeutics, Inc., as of Feb 26, 2026Sold $77K of stock in the past 12 months: 100% to cover taxes.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
39K
shares held after the latest filing, Keros Therapeutics, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
4.7K
shares sold, past 12 months
1
days with sales
$77K
largest single day, Feb 18, 2026
2
companies filed for

Share of stake sold at Keros Therapeutics, Inc. is not shown: most of their shares vested during the period, so a percentage would mislead. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

To cover taxesOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFeb 2026: $77K to cover taxes$77KFebMarAprMayJunJulAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Keros Therapeutics, Inc. (KROS)Chief Financial OfficerApr 8, 2020Feb 26, 2026
Wave Life Sciences, Inc. (WVE)Former Chief Financial OfficerAug 17, 2016Mar 11, 2019

Recent filings

The last day with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.